In clinical trials, common exclusion criteria are PS ≥2, poor baseline hepatic function (elevated aspartate aminotransferase, alanine aminotransferase, and total bilirubin), and hepatitis B or C infection.10, 14. This evidence concerns the gene GPT and hepatitis B virus infection.